Boekhorst Paul Francis Oliv Te Buys 8,000 Shares of ImmuCell (NASDAQ:ICCC) Stock

Posted by Brian Himes on Jun 24th, 2026

ImmuCell Corporation (NASDAQ:ICCC – Get Free Report) CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of the stock in a transaction dated Thursday, June 18th. The stock was acquired at an average cost of $9.49 per share, with a total value of $75,920.00. Following the completion of the transaction, the chief executive officer owned 17,785 shares in the company, valued at approximately $168,779.65. This represents a 81.76% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

ImmuCell Stock Up 1.2%

Shares of ImmuCell stock opened at $9.86 on Wednesday. ImmuCell Corporation has a one year low of $4.52 and a one year high of $10.75. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.82 and a quick ratio of 2.60. The stock’s 50-day moving average is $9.08 and its 200 day moving average is $7.29. The firm has a market cap of $89.23 million, a price-to-earnings ratio of -164.31 and a beta of 0.55.

ImmuCell (NASDAQ:ICCC – Get Free Report) last issued its earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.The business had revenue of $10.36 million during the quarter, compared to the consensus estimate of $5.40 million.

Institutional Trading of ImmuCell

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ICCC. Militia Capital Management LLC bought a new position in ImmuCell in the first quarter worth approximately $114,000. Steadtrust LLC bought a new stake in shares of ImmuCell during the third quarter valued at approximately $198,000. Mesirow Financial Investment Management Inc. raised its position in shares of ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of ImmuCell by 3.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 1,749 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after purchasing an additional 2,907 shares in the last quarter. 13.47% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Read Our Latest Research Report on ImmuCell

ImmuCell Company Profile

(Get Free Report)

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.